Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0021 • ACR Convergence 2021
Unique Alterations in Circulating T Peripheral Helper Cells Are Found in Different Ethnic Groups of ACPA+ Individuals Both At-risk for and with Classified RA
Hideto Takada¹, Yuko Okamoto², Yasuhiro Katsumata³, Jennifer Seifert⁴, Kristen Demoruelle⁵, Jill Norris⁶, Kevin Deane⁷, Masayoshi Harigai³ and V. Michael Holers⁸, ¹Tokyo Women's Medical University School of Medicine, Shinjuku-ku, Japan, ²Tokyo Women's Medical University Division of Rheumatology, 10-22 Kawada-cho, Shinjyuku-ku, Tokyo, Japan, ³Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ⁴University of Colorado School of Medicine, Littleton, CO, ⁵University of Colorado Anschutz Medical Campus, Aurora, CO, ⁶Colorado School of Public Health, Aurora, CO, ⁷University of Colorado Denver, Denver, CO, ⁸University of Colorado, Denver, CO
Background/Purpose: Production of autoantibodies following pathogenic T and B cell interactions precede the development of RA. T follicular helper (Tfh) cells and T peripheral helper…
Abstract Number: 0038 • ACR Convergence 2021
Arthritis Progression in at Risk Individuals Is Associated with ACPAs Not AMPAs
Alexandra Circiumaru¹, Yogan Kisten², Monika Hansson², Heidi Wähämaa³, Meng Sun³, Vijay Joshua³, Hamed Rezaei⁴, Erik Af Klint⁴, Aleksandra Antovic¹, Anca Catrina³ and Aase Haj Hensvold⁵, ¹Division for Rheumatology, Karolinska Institutet; Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden, ²Division for Rheumatology, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet and Karolinska university Hospital, Stockholm, Sweden, ⁴Division for Rheumatology, Karolinska Institutet; Department of Rheumatology, Karolinska University Hospital, Stockholm, Sweden, ⁵Karolinska Institutet, Division for Rheumatology; & Center for Rheumatology, Academic Specialist Center, Stockholm Region, Stockholm, Sweden
Background/Purpose: Individuals with anti citrullinated protein antibodies (ACPA) and musculoskeletal complaints are at high risk for developing rheumatoid arthritis (RA) and often seek medical attention…
Abstract Number: 0120 • ACR Convergence 2021
Fibromyalgianess and Glucocorticoid Persistence Among Patients with Rheumatoid Arthritis
Beth Wallace¹, Meriah Moore², Andrew Heisler³, Lutfiyya Muhammad⁴, Jing Song⁵, Daniel Clauw², Clifton Bingham⁶, Marcy Bolster⁷, Wendy Marder², Tuhina Neogi⁸, Alyssa Wohlfahrt⁹, Dorothy Dunlop¹⁰ and Yvonne Lee¹⁰, ¹Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Bronson Rheumatology Specialists, Kalamazoo, MI, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Worthington, IL, ⁶Johns Hopkins University, Baltimore, MD, ⁷Massachusetts General Hospital, Boston, MA, ⁸Boston University School of Medicine, Boston, MA, ⁹Tufts University School of Medicine, Boston, MA, ¹⁰Northwestern University, Chicago, IL
Background/Purpose: Over one-third of patients with rheumatoid arthritis (RA) exhibit evidence of fibromyalgianess, a cluster of somatic symptoms associated with increased sensitivity to painful stimuli.…
Abstract Number: 0182 • ACR Convergence 2021
Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis
Irina Gessl¹, Mihaela Popescu², Gabriela Supp¹, Martina Durechova¹, Michael Zauner¹, Josef Smolen¹, Daniel Aletaha³ and Peter Mandl¹, ¹Medical University of Vienna, Vienna, Austria, ²Maisonneuve Rosemont Hospital, Longueuil, QC, Canada, ³Medical University Vienna, Vienna, Austria
Background/Purpose: In rheumatoid arthritis (RA) and psoriatic arthritis (PsA), swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, recent…
Abstract Number: 0277 • ACR Convergence 2021
Best Cardiovascular Risk Algorithm to Predict Abnormalities in Left Ventricular Geometry in Rheumatoid Arthritis Patients
Alejandra Rodriguez-Romero, Jose Azpiri-Lopez, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose A. Davila-Jimenez, Natalia Guajardo-Jauregui, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Alan De Leon-Yañez and Catalina Andrade-Vazquez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: A relationship between rheumatoid arthritis (RA) and the presence of abnormalities in left ventricular (LV) geometry such as eccentric remodeling has recently been determined,…
Abstract Number: 0295 • ACR Convergence 2021
Weight History and Associations with Cardiovascular Risk in Patients with Rheumatoid Arthritis
Lydia Federico¹, Kaleb Michaud², Kristin Wipfler³, Gulsen Ozen⁴ and Joshua Baker¹, ¹University of Pennsylvania, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴University of Nebraska Medical Center, Bellevue, NE
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of mortality in rheumatoid arthritis (RA), but traditional CVD risk factors may not accurately characterize risk. For…
Abstract Number: 0514 • ACR Convergence 2021
Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts
Ruby Siegel¹, Anil singh¹, Judy Vinh¹, H. Mark Kenney², Edward Schwarz³, David Fox⁴, Sadik Khuder⁵ and Salah-uddin Ahmed¹, ¹Washington State University, Spokane, WA, ²University of Rochester Medical Center, Rochester, NY, ³University of Rochester, Rochester, NY, ⁴Division of Rheumatology, University of Michigan Medical School, Ann Arbor, MI, ⁵Department of Medicine and Public Health, University of Toledo,, Toledo, OH
Background/Purpose: TNF-α drives RA synovial fibroblast (RASF)-mediated hyperplasia and joint tissue destruction. Extracellular sulfatase-2 (Sulf-2) influences receptor/ligand binding and subsequent signaling of chemokines, cytokines, and…
Abstract Number: 0577 • ACR Convergence 2021
Comorbidity Burden as Scored Using the Rheumatic Disease Comorbidity Index (RDCI) Is Associated with Varying Treatment Patterns in Patients with Inflammatory Arthritis – a Study Using the EHR-Derived Rheumatic and Arthritis Disease Information Registry (RADIR)
Diviya Rajesh, Deanna Jannat-Khah, Huong Do, Jonah Levine, Medha Barbhaiya, Lisa Mandl and Vivian Bykerk, Hospital for Special Surgery, New York, NY
Background/Purpose: Higher comorbidity burden (CB) has been associated with treatment choices in RA, but not assessed in populations including multiple forms of inflammatory arthritis (IA)…
Abstract Number: 0607 • ACR Convergence 2021
Validation Studies of Rheumatoid Arthritis Patient-Reported Outcome Measures in Diverse Populations at Risk for Inequity: A Systematic Review
Cheryl Barnabe¹, Aimee Wattiaux², Jennifer Petkovic³, Dorcas Beaton⁴, Beverley Shea³, Regina Greer-Smith⁵, Jennifer Humphreys⁶, Christie Bartels⁷, Peter Tugwell³ and Valerie Umaefulam¹, ¹University of Calgary, Calgary, AB, Canada, ²University of Wisconsin, Madison, WI, ³University of Ottawa, Ottawa, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Healthcare Research Associates, Hazel Crest, IL, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Existing patient-reported outcome measures (PROMs) in rheumatoid arthritis (RA) may be limited in their applicability to populations that experience inequities. We conducted a systematic…
Abstract Number: 0762 • ACR Convergence 2021
Validity of the Musculoskeletal Health Questionnaire: Real World Analysis of Data Collection via an Electronic Patient Reported Outcome Platform
Amy Boalch¹, Sam Norton¹, Sophia Steer², Nicky Wilson² and James Galloway³, ¹King's College London, London, United Kingdom, ²King's College Hospital, London, United Kingdom, ³Kings College London, London, United Kingdom
Background/Purpose: The Musculoskeletal Health Questionnaire (MSK-HQ) is a patient reported outcome measure (PROM) validated to assess disease outcomes in patients with MSK disorders. This study…
Abstract Number: 0802 • ACR Convergence 2021
Infection in Rheumatoid Arthritis Patients Treated with Golimumab
Louis Bessette¹, Proton Rahman², John Kelsall³, Jane Purvis⁴, Emmanouil Rampakakis⁵, Allen Lehman⁶, Meagan Rachich⁶, Francois Nantel⁷ and Odalis Asin-Milan⁶, ¹Laval University, Québec City, QC, Canada, ²Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ³Providence Health Care, Vancouver, BC, Canada, ⁴Peterborough Education, Peterborough, ON, Canada, ⁵JSS Medical Research, Montréal, QC, Canada, ⁶Janssen Inc., Toronto, ON, Canada, ⁷., Montreal, ON, Canada
Background/Purpose: Biologic use in RA is a well-characterized risk factors for infections. The aim of this analysis was to characterize the incidence of infection in…
Abstract Number: 0820 • ACR Convergence 2021
The PROPER Study: Results of the First 48-week Interim Analysis of a Pan-EU Real-world Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis
Ulf Müller-Ladner¹, Karl Gaffney², Deepak Jadon³, Ulrich Freudensprung⁴ and Janet Addison⁵, ¹JLU Giessen, Campus Kerckhoff, Dept. Rheum & Clin Immunol, Bad Nauheim, Germany, ²Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ³Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, ⁴Biogen International GmbH, Baar, Switzerland, ⁵Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB5, an adalimumab (ADL) biosimilar, received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I…
Abstract Number: 0837 • ACR Convergence 2021
Sustainability of Response Between Upadacitinib and Adalimumab in Patients with Rheumatoid Arthritis: Results Through 3 Years from the SELECT-COMPARE Trial
Peter Nash¹, Arthur Kavanaugh², Maya Buch³, Bernard Combe⁴, Louis Bessette⁵, In-Ho Song⁶, Tim Shaw⁷, Yanna Song⁶, Jessica Suboticki⁶ and Roy Fleischmann⁸, ¹Griffith University, Brisbane, Australia, ²University of California San Diego, La Jolla, CA, ³University of Leeds, Leeds, United Kingdom, ⁴CHU Montpellier Montpellier University, Montpellier, France, ⁵Laval University, Québec City, QC, Canada, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Inc., North Chicago, ⁸Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: The primary treatment target for patients with active rheumatoid arthritis (RA) is sustained clinical remission (REM) or low disease activity (LDA).1,2 A greater proportion…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 1066 • ACR Convergence 2021
Evaluation of a Non-Face to Face Multidisciplinary Health Care Model in a Population with Rheumatoid ArthritisVulnerable to Covid-19 in a Health Emergency Situation
Pedro Santos-Moreno¹, Rosangela Casanova², Gabriel-Santiago Rodríguez-Vargas², Laura Villareal¹, Jaime-Andrés Rubio², Josefina Chávez-Chávez², Diana Patricia Rivera-Triana², Ruth Alexandra Castiblanco-Montañez², Sandra Milena Hernández-Zambrano² and Adriana Rojas-Villarraga², ¹BIOMAB IPS, Bogotá, Colombia, ²Fundación Universitaria de Ciencias de la Salud-FUCS, Bogotá, Colombia
Background/Purpose: The COVID-19 pandemic impacted everyday practice pattern of health care in rheumatoid arthritis (RA) patients. The objective was to evaluate the implementation of a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].